OmniComm Systems, Inc. (OTC: OMCM.OB), a global provider of eClinical solutions, announced that it released a new Application Programming Interface (API), OmniConnect™. OmniConnect is a REST, web services, API based on an extended CDISC ODM dataset. The use of REST web services in the API is the first of its kind in the industry. “This new API follows OmniComm’s continued focus on interoperability and providing value based solutions,” said Randy Smith, CTO of OmniComm Systems. “OmniConnect brings together complex clinical trial management functionality with our TrialMaster™ EDC solution in a single, integrated database. By receiving a consistent stream of data, TrialMaster enables sponsors and sites to take advantage of real-time integration of disparate information and data sources.”
“This very flexible solution has many applications and has already been deployed with customers in on-going clinical studies, both in the US and in Europe. One of our partners, PharmaPros, has utilized OmniConnect to support real-time reporting requirements for three studies, using their trial management application, Dataflow Manager,” said Stephen Johnson, COO of OmniComm Systems.
A European technology partner is currently deploying OmniConnect to extract clinical trial data from TrialMaster to their IVR/IWR system and to manage effectively their Sponsor’s trial in a cost-effective way. OmniComm’s Johnson added, “Other uses include tracking and report enrollment, safety data, supply management such as dispensation and reconciliation of study drugs, exports to a CTMS; imports of data from central labs, ECG, IVRS and from our soon to be released Phase I data collection and management system, TrialOne™. ”
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.